Table 2.

Multivariate analysis for the overall survival of MDS

Parameter	p-value	HR (95%CI)
Sex	0.202	0.823 (0.610–1.110)
(male vs. female)
Age	0.001	1.728 (1.255–2.379)
(> 60 vs. ≤ 60)
ANC, 10^9/L	0.512	1.113 (0.807–1.535)
(< 0.8 vs. ≥ 0.8)
Cytogenetic group
Very poor	0.000	1.657 (1.256–2.187)
Poor
Intermediate
Good
Very good
BM blasts percentage,%	0.000	1.946 (1.438–2.632)
(> 10 vs.5–10 vs. > 2− < 5 vs. ≤ 2)
Infection	0.000	2.488 (1.749–3.538)
IPSS-R risk category
Very low	0.038	0.628 (0.405–0.974)
Low
Intermediate
High
Very high
Genetic mutations
TP53 (Mutation type vs. wild type)	0.004	1.880 (1.222–2.893)
TET2 (Mutation type vs. wild type)	0.005	1.565 (1.090–2.249)
Diabetes mellitus	0.762	1.050 (0.765–1.442)
Serum erythropoietin, mIU/ml	0.318	1.194 (0.843–1.692)
(≤ 500 vs. > 500)
HGB, g/L	0.057	0.741 (0.544–1.009)
(≥ 100 vs. 80− < 100 vs. < 80)
PLT, 10^9/L	0.246	1.287 (0.840–1.971)
(< 50 vs. 50− < 100 vs. ≥ 100)
Serum ferritin, ng/ml	0.318	1.194 (0.843–1.692)
(> 500 vs. ≤ 500)

ANC Absolute neutrophil count; BM bone marrow; HGB homoglobin; HR hazard ratio; IPSS-R revised international prognostic scoring system; PLT platelet